Calidi Biotherapeutics, Inc. Common Stock CLDI 深 沪
已收盘 12-24 16:00:00 美东时间
1.29
-0.010
-0.77%
华盛通- 最 高1.30
- 今 开1.26
- 成交量 2.63万股
- 最 低 1.26
- 昨 收 1.30
- 总市值 371.09万
- 52周最高 19.20
- 市盈率 静 --
- 换手率 0.91%
- 52周最低 1.10
- 委 比 -33.33%
- 总股本 287.67万
- 历史最高 2886.00
- 量 比 0.28
- 振 幅 3.08%
- 历史最低 1.26
- 每 手 1
- 风险率 4.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share
11-14 05:22
Calidi Biotherapeutics Presents Data On Its First Therapeutic Candidate From Its Redtail Platform CLD-401
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented new data
11-10 21:12
Calidi Biotherapeutics Presents New Data On First Therapeutic Candidate From RedTail Platform, CLD-401, At SITC Annual Meeting
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the
10-30 20:06
Calidi Biotherapeutics Forms Scientific Advisory Board To Further Develop RedTail Platform And Advance CLD-401 Into Clinic
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the formation
10-22 20:05
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
<p>Calidi Biotherapeutics announced the formation of its Scientific Advisory Board (SAB) to advance its RedTail platform and lead candidate CLD-401. The RedTail platform uses an enveloped vaccinia virus to deliver genetic medicines systemically and target metastatic sites. CLD-401 aims to replicate in tumors, induce immune responses, and express IL-15 superagonist. The SAB includes leading experts in drug development and oncology. The company is ...
10-22 12:00
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
Calidi Biotherapeutics' CEO, Eric Poma, will participate in the Oncology Venture, Innovation, and Partnering Summit to discuss the company's RedTail platform, designed to deliver genetic medicines to metastatic sites. The platform aims to protect viruses from immune clearance and enhance tumor targeting. The company's lead candidate is in IND-enabling studies for cancers like non-small cell lung and ovarian cancer. The event, held in Boston, incl...
09-29 12:00
Calidi Biotherapeutics Streamlines Leadership with Role Elimination
Calidi Biotherapeutics ( ($CLDI) ) just unveiled an update. On September 16, 20...
09-20 05:37
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Calidi Biotherapeutics Updates Presentation Disclosure
Calidi Biotherapeutics ( ($CLDI) ) just unveiled an update. On August 29, 2025,...
08-30 05:51
Calidi Biotherapeutics Completes $6.9M Public Offering
An announcement from Calidi Biotherapeutics ( ($CLDI) ) is now available. On Au...
08-23 05:47
